I provide and supervise radiation oncology specialty services at Jameson Radiation Oncology clinic in New Castle, Pennsylvania, one of the most advanced radiation oncology centers within 20 miles of the center. I specialize in treating all sorts of cancers that are amenable to treatment with external beam radiation therapy, including 3D conformal radiation therapy (3D-CRT), intensity modulated radiation therapy (IMRT), computer optimized radiation therapy planning strictly confined to the targeted organs in order to minimize radiation dose to adjacent, normal tissues, and, for extra precise and accurate treatment when needed, image guided radiation therapy (IGRT), which further adds the ability to take a daily x-ray or CT scan in treatment position just before a given treatment starts for added precision. I also offer brachytherapy services for lung and prostate cases, implanting them with radioactive seeds to provide highly conformal target coverage when appropriate. I provide administration of radioactive isotopes, in conjunction with Jameson Hospital Nuclear Medicine Department, such as thyroid-seeking radioactive 131I to treat thyroid cancer and hyperthyroidism, and bone seeking radioisotopes to target metastatic cancer to bone, such as Xofigo (223Ra) and Quadramet (153Sm.)
I serve on several local committees, such as the UPMC Jameson Cancer Committee, the Jameson Hospital Radiation Safety Committee, the UPMC/Jameson Cancer Center Radiation Safety (RS) Committee, the UPMC/Jameson Cancer Center Safety Committee, and the Jameson Hospital Multidisciplinary Tumor Board, which meets weekly to discuss difficult cases and dilemmas in treating cancer patients. I co-chair, with Dr. Gregory Bednarz, the UPMC CancerCenter Radiation Safety Oversight Committee (RSOC.) I attend and report to the UPMC/Jameson Cancer Center joint venture board meetings as a non-voting attendee. I provide leadership skills to two charitable cancer-based patient support organizations and starting in 2014 was asked to serve as vice president of one of them, the New Castle Cancer Support Group. I won one of the “C.A.R.E. Heroes of Distinction” awards of July 2013 and again in 2015, as nominated by patient family members and as presented by CEO of UPMC Jameson Hospital, Doug Danko. I occasionally participate in activities teaching radiation oncology residents from Pittsburgh about the specialty, and I deliver talks to cancer groups and talk about my specialty on local radio. I have, for example, spoken several times on WKST radio AM-1200 on the “Jameson Health Talk” program, explaining my and the role of the UPMC CancerCenter in local care and treatment of local cancer patients and what technology is available.
“Occurrence and implications of myelosuppression during concurrent therapy on RTOG 0825,” R Zhou, M Scheurer, MR Gilbert, ML Bondy, EP Sulman, Y Yuan, Y Liu, E Vera-Bolanos, MM Wendland, DG Brachman, JD Bearden, SL McGovern, SS Wilson, KD Judy, HI Robins, GK Hunter, SL Pugh, & TS Armstrong, abstract presented at Society for Neuro-Oncology's 21st Annual Scientific Meeting on November 17 - 20, 2016, abstract permanent program number, #ACTR-21 and published in the November supplement of the journal Neuro-Oncology. Supported by NIH grant R01NR013707, NCI grants U10CA21661, U10CA180868, U10CA180822, U10CA37422, and U24CA114734, Genentech, and Voices Against Brain Cancer Foundation
“Polymorphisms Risk Modeling for Vascular Toxicity in Patients with Glioblastoma Treated on NRG Oncology/RTOG 0825,” R Zhou, M Scheurer, MR Gilbert, ML Bondy, EP Sulman, Y Yuan, Y Liu, E Vera-Bolanos, MM Wendland, DG Brachman, JD Bearden, SL McGovern, SS Wilson, KD Judy, HI Robins, GK Hunter, SL Pugh, & TS Armstrong, abstract presented at ASCO annual meeting, June 3-7, 2016. Supported by NIH grant R01NR013707, NCI grants U10CA21661, U10CA180868, U10CA180822, U10CA37422, and U24CA114734, Genentech, and Voices Against Brain Cancer Foundation
“Risk Modeling for Vascular Toxicity in Patients with Glioblastoma (GBM) treated on RTOG 0825,” Zhou, R., Scheurer, M., Gilbert, M.R., Bondy, M., Sulman, E., Yuan, Y., Liu, Y., Vera-Bolanos, E., Wendland, M., Brachman, D., Bearden, J., McGovern, S., Wilson, S., Judy, K., Robins, H., Hunter, G., Crocker, I., Chao, S., Kaluza, V., Pugh, S.L., & Armstrong, T.S., abstract for SNO2015 meeting. Supported by NIH grant-1R01NR013707-01A1
“Excellent Long Term Biochemical Failure Free Survival and Low Rates of Toxicity in a Large Cohort of Patients with Prostate Adenocarcinoma Treated to 75 to 78 Gy with IMRT in Agreement with QUANTEC Modeling,” C. A. Smith, D. L. Erickson, L. L. Greer, D. A. Gant, R. B. Wilder, P. Y. Song, S. Wilson, D. G. McLeod, A. E. Graff, J. M. Wei, R. M. Lystrup, A. T. Hickerson, and J. J. O'Connell, submitted February 25, 2015 for abstract at ASTRO 2015
“Patterns of Care for Low-Dose Rate Permanent Prostate Seed Brachytherapy Implants (PSI) in a Large, Academic-Based Multi-Center Practice", Raymond Wynn, M.D., Carol Scicutella, M.D., Sushil Beriwal, James Sinicki, Dwight E. Heron, M.D., F.A.C.R.O., Steven Wilson, M. D. and Julian W. Proctor, M. D., Ph. D., reference 0039, accepted for poster presentation at ACRO 2015 in Washington, D.C.
“Inexpensive Solutions to Enhance Remote Cancer Care in Community Hospitals,” Larry L Schenken, Ph.D., Susan M Rakfal, M.D., Dwight E. Heron, M.D., Steven Wilson, M. D. and Julian W. Proctor, M. D., Ph. D., Community Oncology, 2013; 10:316-324, November 2013, DOI 10.12788/j.cmonc.0017, manuscript ID CO-D-12-00027. http://www.oncologypractice.com/fileadmin/content_pdf/co/CO_nov_316_Schenken_Orig_Res.pdf